Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study

収録刊行物

• Lancet Oncol

  Lancet Oncol 12 735-742, 2011